A phase II trial of personalized peptide vaccination for nine kinds of cancers
Phase 2
- Conditions
- Prostate cancer, Urothelial cancer, Breast cancer, Lung cancer, Ovarian cancer, Gastric cancer, Colon cancer, Liver cancer, Pancreatic cancer
- Registration Number
- JPRN-UMIN000029789
- Lead Sponsor
- Kurume University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 900
Inclusion Criteria
Not provided
Exclusion Criteria
The following patients must be excluded 1) Patients with severe underlying diseases conditions (active and severe infection, circulatory diseases, respiratory diseases, renal diseases, immunodeficiencies, disturbance of coagulation,et al.) 2) Patients with the past history of severe allergic reactions. 3) Females Pregnant or nursing patients. Males Patients who do not accept contraception during vaccination period and until 70 days after the last vaccination. 4) Patients who are judged inappropriate for entry to this clinical trial by examination medical attendant.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Peptide-specific immune responses in PBMCs at the end of 1st course
- Secondary Outcome Measures
Name Time Method Overall suvival Adverse events of the entire period(safety assessments)